Compass Therapeutics (CMPX) Short term Debt (2019 - 2021)

Compass Therapeutics' Short term Debt history runs 3 years deep, the most recent figure standing at $3.7 million for Q3 2021.

• In Q3 2021, Short term Debt fell 49.82% year-over-year to $3.7 million; the TTM figure through Sep 2021 stood at $3.7 million (down 49.82% YoY), while the FY2020 annual figure was $7.5 million, up 1411.54% from the prior year.
• Short term Debt came in at $3.7 million for Q3 2021 at Compass Therapeutics, down from $7.5 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $7.5 million in Q1 2021 to a low of $494000.0 in Q4 2019.
• A 3-year average of $5.7 million and a median of $7.5 million in 2020 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt soared 1411.54% in 2020 and plunged 49.82% in 2021, its largest moves.
• Compass Therapeutics' Short term Debt stood at $494000.0 in 2019, then jumped by 1411.54% to $7.5 million in 2020, then sank by 49.86% to $3.7 million in 2021.
• According to Business Quant data, Short term Debt over the past three periods registered $3.7 million, $7.5 million, and $7.5 million for Q3 2021, Q1 2021, and Q4 2020 respectively.

Peer Comparison